Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Hoffmann-La Roche
Charles C Wykoff; Francis Abreu; Anthony P Adamis; Karen Basu; David A Eichenbaum; Zdenka Haskova; Hugh Lin; Anat Loewenstein; Shaun Mohan; Ian A Pearce; Taiji Sakamoto; Patricio G Schlottmann; David Silverman; Jennifer K Sun; John A Wells; Jeffrey R Willis; Ramin Tadayoni; YOSEMITE and RHINE Investigators